Skip to content

Timing of VTE Prophylaxis in TBI

Timing of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03081169
Enrollment
0
Registered
2017-03-16
Start date
2017-04-03
Completion date
2019-08-12
Last updated
2019-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)

Brief summary

This study compares the efficacy and complication rates of early (24 hours) versus late (72 hours) VTE prophylaxis administration to TBI patients. Patients in both treatment groups will be monitored for development of VTE as well as complications from bleeding after commencement of VTE prophylaxis.

Detailed description

This a randomized prospective study that compares the efficacy and complication rates of early (24 hours) versus late (72 hours) VTE prophylaxis administration to TBI patients. Patients who are identified as having an intracranial injury will be randomized to early versus late VTE prophylaxis using a 1:1 random numbers allocation. Patients in both treatment groups will be monitored for development of VTE, primarily with scheduled duplex ultrasound studies of the lower extremities. Any clinical suspicion of VTE will also be investigated with duplex ultrasound and/or CT angiogram of the chest. Patients will be monitored for development of complications from bleeding post commencement of VTE prophylaxis. Intracranial bleeding complications will be monitored by physical examination and CT scanning of the head when indicated. Patients who undergo craniotomy or craniectomy will have VTE prophylaxis started 72 hours post-surgery and will undergo CT scan of the head (to assure bleeding stabilization) prior to administration of VTE prophylaxis.

Interventions

DRUGEnoxaparin Sodium 150 MG/ML Prefilled Syringe

The same drugs and dosages will be used in both groups, with only the timing being different

DRUGHeparin

The same drugs and dosages will be used in both groups, with only the timing being different

Sponsors

Loyola University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Traumatic brain injury * Intracranial hemorrhage on CT scan

Exclusion criteria

* Under the age of 18 * Pregnant * Die within 24 hours of admission * Hospital stay less than 5 days * Contraindications to enoxaparin or heparin * Coagulopathy at 24 hours post-injury defined as INR\>1.6 aPTT\>2x normal, or platelet counts\<50k * Known history of VTE

Design outcomes

Primary

MeasureTime frameDescription
VTEOutcomes will be assessed until hospital discharge. Data will be presented at study completion with the expectation of approximately 2 years.Rate of venous thromboembolism (DVT or PE)

Secondary

MeasureTime frameDescription
Bleeding complicationsOutcomes will be assessed until hospital discharge. Data will be presented at study completion with the expectation of approximately 2 years.Rate of expanding intracranial hemorrhage

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026